Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

Boehringer Ingelheim and Lilly have developed a joint education campaign about the role of sodium glucose co-transporters (SGLT) in maintaining blood sugar balance for type 2 diabetes patients.

The campaign has been designed to provide healthcare professionals (HCPs) with a better understanding of the emerging science of using SGLTs to maintain glucose homeostasis, or blood sugar balance, which enables glucose entering the kidneys to find its way back into the bloodstream instead of being passed in the urine.

The initiative includes a microsite - www.sglt.com - featuring a short educational video, Glucose Perspectives, which was created by the Royal Society for the encouragement of Arts, Manufacturing and Commerce (RSA). Viewers are invited to sign up for further learning options that will be offered throughout the year.

“The contribution of insulin resistance and impaired beta-cell function in the physiopathology of type 2 diabetes mellitus has been extensively studied,” said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim.

“The contributing role of persistently high glucose levels in the progression of type 2 diabetes has led to the need for a better understanding of how glucose is reabsorbed by the kidneys.

“The Boehringer Ingelheim and Lilly Diabetes alliance is very pleased to offer healthcare professionals an educational resource they can use at their convenience to gain greater knowledge of this process.”

Germany-headquartered Boehringer Ingelheim and US-based Eli Lilly announced a diabetes alliance at the beginning of 2011, which has focused on three pipeline compounds representing several of the largest treatment classes.

Earlier this year, the partnership filed its new SGLT-2 inhibitor, Empagliflozin, for European approval.

8th May 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics